Patents by Inventor Katherine L. Molnar-Kimber

Katherine L. Molnar-Kimber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7897733
    Abstract: Provided are rapamycin conjugates which are useful as immunogenic molecules for the generation of antibodies specific for rapamycin, for measuring levels of rapamycin or derivatives thereof; for isolating rapamycin binding proteins; and detecting antibodies specific for rapamycin or derivatives thereof. This invention also provides a rapamycin specific monoclonal antibody.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: March 1, 2011
    Assignee: Pfizer, Inc.
    Inventors: Katherine L. Molnar-Kimber, Craig E. Caufield, Timothy D. Ocain
  • Patent number: 7279561
    Abstract: Provided are rapamycin conjugates which are useful as immunogenic molecules for the generation of antibodies specific for rapamycin, for measuring levels of rapamycin or derivatives thereof; for isolating rapamycin binding proteins; and detecting antibodies specific for rapamycin or derivatives thereof. This invention also provides a rapamycin specific monclonal antibody.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: October 9, 2007
    Assignee: Wyeth
    Inventors: Katherine L. Molnar-Kimber, Craig E. Caufield, Timothy D. Ocain
  • Patent number: 7279562
    Abstract: Provided are rapamycin conjugates which are useful as immunogenic molecules for the generation of antibodies specific for rapamycin, for measuring levels of rapamycin or derivatives thereof; for isolating rapamycin binding proteins; and detecting antibodies specific for rapamycin or derivatives thereof. This invention also provides a rapamycin specific monoclonal antibody.
    Type: Grant
    Filed: April 18, 2002
    Date of Patent: October 9, 2007
    Assignee: Wyeth
    Inventors: Katherine L. Molnar-Kimber, Craig E. Caufield, Timothy D. Ocain
  • Publication number: 20040157775
    Abstract: This invention comprises antibodies to rapamycin effector proteins, and preparations thereof. Novel Rapamycin-FKBP12 binding proteins, nucleic acids and their fragments are also described, as are related methods and therapeutic uses of the proteins, nucleic acids, and antibodies.
    Type: Application
    Filed: October 15, 2003
    Publication date: August 12, 2004
    Applicants: Wyeth, The Trustees of Columbia University
    Inventors: Thomas J. Caggiano, Yanqiu Chen, Amedeo A. Failli, Katherine L. Molnar-Kimber, Koji Nakanishi
  • Patent number: 6713607
    Abstract: This invention comprises novel Rapamycin-FKBP12 binding proteins of mammalian origin for identification, design and synthesis of immunomodulatory, anti-restenosis or anti-tumor agents, as well as fragments of the proteins and the DNA, cDNA, antisense RNA and DNA segments corresponding to the proteins. This invention also comprises methods for isolating the proteins and therapeutic uses related to the proteins.
    Type: Grant
    Filed: September 13, 2001
    Date of Patent: March 30, 2004
    Assignee: Wyeth
    Inventors: Thomas J. Caggiano, Yanqiu Chen, Amedeo A. Failli, Katherine L. Molnar-Kimber, Koji Nakanishi
  • Patent number: 6541612
    Abstract: Provided are rapamycin conjugates which are useful as immunogenic molecules for the generation of antibodies specific for rapamycin or a derivative thereof, for measuring levels of rapamycin or derivatives thereof; for isolating rapamycin binding proteins; and detecting antibodies specific for rapamycin or derivatives thereof. This invention also provides monoclonal antibodies specific for rapamycin or a ring opened derivative of rapamycin.
    Type: Grant
    Filed: February 2, 2001
    Date of Patent: April 1, 2003
    Assignee: Wyeth
    Inventors: Katherine L. Molnar-Kimber, Craig E. Caufield, Timothy D. Ocain, Amadeo A. Failli
  • Publication number: 20030032775
    Abstract: This invention comprises novel Rapamycin-FKBP12 binding proteins of mammalian origin for identification, design and synthesis of immunomodulatory, anti-restenosis or anti-tumor agents, as well as fragments of the proteins and the DNA, cDNA, antisense RNA and DNA segments corresponding to the proteins. This invention also comprises methods for isolating the proteins and therapeutic uses related to the proteins.
    Type: Application
    Filed: September 13, 2001
    Publication date: February 13, 2003
    Applicant: American Home Products
    Inventors: Thomas J. Caggiano, Yanqiu Chen, Amedeo A. Failli, Katherine L. Molnar-Kimber, Koji Nakanishi
  • Publication number: 20020151088
    Abstract: Provided are rapamycin conjugates which are useful as immunogenic molecules for the generation of antibodies specific for rapamycin, for measuring levels of rapamycin or derivatives thereof; for isolating rapamycin binding proteins; and detecting antibodies specific for rapamycin or derivatives thereof. This invention also provides a rapamycin specific monoclonal antibody.
    Type: Application
    Filed: April 18, 2002
    Publication date: October 17, 2002
    Inventors: Katherine L. Molnar-Kimber, Craig E. Caufield, Timothy D. Ocain
  • Patent number: 6328970
    Abstract: Provided are rapamycin conjugates which are useful as immunogenic molecules for the generation of antibodies specific for rapamycin or a derivative thereof, for measuring levels of rapamycin or derivatives thereof; for isolating rapamycin binding proteins; and detecting antibodies specific for rapamycin or derivatives thereof. This invention also provides monoclonal antibodies specific for rapamycin or a ring opened derivative of rapamycin.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: December 11, 2001
    Assignee: American Home Products Corporation
    Inventors: Katherine L. Molnar-Kimber, Craig E. Caufield, Timothy D. Ocain, Amadeo A. Failli
  • Patent number: 6313264
    Abstract: This invention comprises novel Rapamycin-FKBP12 binding proteins of mammalian origin for identification, design and synthesis of immunomodulatory, anti-restenosis or anti-tumor agents, as well as fragments of the proteins and the DNA, cDNA, antisense RNA and DNA segments corresponding to the proteins. This invention also comprises methods for isolating the proteins and therapeutic uses related to the proteins.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 6, 2001
    Assignees: American Home Products Corporation, The Trustees of Columbia University
    Inventors: Thomas J. Caggiano, Yanqiu Chen, Amedeo A. Failli, Katherine L. Molnar-Kimber, Koji Nakanishi
  • Publication number: 20010010920
    Abstract: Provided are rapamycin conjugates which are useful as immunogenic molecules for the generation of antibodies specific for rapamycin or a derivative thereof, for measuring levels of rapamycin or derivatives thereof; for isolating rapamycin binding proteins; and detecting antibodies specific for rapamycin or derivatives thereof. This invention also provides monoclonal antibodies specific for rapamycin or a ring opened derivative of rapamycin.
    Type: Application
    Filed: February 2, 2001
    Publication date: August 2, 2001
    Inventors: Katherine L. Molnar-Kimber, Craig E. Caufield, Timothy D. Ocain, Amadeo A. Failli
  • Patent number: 5504091
    Abstract: A compound of the structure ##STR1## R.sup.1 and R.sup.2 are each, independently, hydrogen or ##STR2## X is ##STR3## Y is ##STR4## Z is --CH.sub.2 --, --S--S--, or ##STR5## R.sup.3 is hydrogen, alkyl, arylalkyl, alkenyl, alkynyl, --(CH.sub.2).sub.q CO.sub.2 R.sup.5, --(CH.sub.2).sub.r NR.sup.6 R.sup.7, carbamylalkyl, aminoalkyl, hydroxyalkyl, guanylalkyl, mercaptoalkyl, alkylthioalkyl, indolylmethyl, hydroxyphenylmethyl, imidazoylmethyl, halo, trifluoromethyl, or phenyl which is optionally mono-, di-, or tri-substituted;R.sup.4, R.sup.6, and R.sup.7 are each, independently, hydrogen, alkyl, or arylalkyl;R.sup.5 is hydrogen, alkyl, arylalkyl, alkenyl, alkynyl, or phenyl which is optionally mono-, di-, or tri-substituted;h=0-1;j=0-1;m=0-6;n=0-6;p=0-10;q=0-10;r=0-6;with the proviso that R.sup.1 and R.sup.2 are not both hydrogen, or a pharmaceutically acceptable salt thereof which is useful for inducing immunosuppression; in the treatment of transplantation rejection, host vs.
    Type: Grant
    Filed: April 14, 1994
    Date of Patent: April 2, 1996
    Assignee: American Home Products Corporation
    Inventors: Katherine L. Molnar-Kimber, Timothy D. Ocain, Steven K. Vernon, John J. Huang